Background and objective: Pleuroscopy is the test of choice for patients with suspected malignant pleural effusion and negative cytology. Biopsies negative for malignancy are frequently attributed to non-specific pleuritis, which poses a dilemma in patients with a known active malignancy, raising concern for a falsenegative result. Our primary objective was to determine the outcomes of patients with active malignancy who had a non-malignant diagnosis on pleuroscopy. Methods: Retrospective review of all pleuroscopy cases from January 2005 to January 2015 at our institution was conducted. Biopsies were categorized by histopathology as malignant, eosinophilic or non-specific pleuritis. Malignant histopathology was considered a true positive. Eosinophilic or non-specific pleuritis was categorized as malignant, if malignancy was later identified during follow-up, or chemotherapy induced, possible radiation induced, other paramalignant, other benign or idiopathic. Results: Of the 199 pleuroscopy cases reviewed, 172 (86%) had a history of active malignancy. On histopathology, 73 (42%) had malignancy, 9 (5%) had eosinophilic pleuritis and 90 (52%) had non-specific pleuritis. Three patients with non-specific pleuritis were diagnosed with malignancy at follow-up. Pleuritis in 24 patients was chemotherapy induced, 27 were possibly radiation induced, 11 were other paramalignant and 3 were other benign. Idiopathic pleuritis was diagnosed in 31 patients. Patients were monitored for a mean of 23 AE 11 months. Conclusion: The prevalence of malignant pleural disease was lower than expected for our patient population. Patients with no malignancy on histopathology were most likely to have non-specific pleuritis, a cause for which was identified in a majority of patients after clinical review.
INTRODUCTION
Malignant pleural effusion confers a poor prognosis for patients with solid tumour or haematological malignancy as it signifies advanced disease. 1, 2 However, patients with malignancy may also develop paramalignant effusions, which are usually due to treatment effect, pulmonary embolism, radiation therapy or chemotherapy. 3, 4 Pleural inflammation underlies the formation of most exudative paramalignant effusions and is a common histological finding irrespective of the underlying aetiology. 5 The diagnostic cornerstone of malignant pleural effusion is the presence of malignant cells in the pleural cavity. In patients with suspected malignant pleural effusion whose pleural fluid cytology is negative for malignancy, the next recommended diagnostic step is pleural biopsy. In such cases, pleuroscopy with pleural biopsy has a sensitivity of 95% for diagnosing pleural malignancy. [6] [7] [8] Although histopathology is specific for malignancy, it lacks specificity for causes of benign pleuritis. In such cases, biopsies are frequently reported as benign inflammation of uncertain aetiology, usually referred to as 'non-specific pleuritis'. 8 A histology report of nonspecific pleuritis can clinically be useful, for example, in a population where the purpose of pleuroscopy was to rule out malignancy. However, in patients with 
SUMMARY AT A GLANCE
Non-specific pleuritis diagnosed on pleuroscopy in patients with active malignancy and pleural effusion represents a diagnostic dilemma. We studied outcomes in 199 patients with active malignancy who underwent pleuroscopy. The sensitivity of pleuroscopy was high and most patients without malignancy had non-specific pleuritis, which was later categorized after clinical review.
suspected mesothelioma, where 8.3-12% will develop mesothelioma after negative pleuroscopy, 8, 9 or in patients with active malignancy, where the pretest probability of malignancy is high, non-specific pleuritis represents a diagnostic dilemma.
Our primary objective was to determine outcomes in patients with active malignancy who had a nonmalignant diagnosis on pleuroscopy. Secondary objectives include evaluating the performance of pleuroscopy in patients with active malignancy, determining the prevalence of malignant pleural disease in a cohort of patients with active cancer and further categorizing those with non-malignant effusions.
METHODS
We performed a retrospective review of all pleuroscopy cases from January 2005 to January 2015 at our institution. The Institutional Review Board Committee approved this study, with protocol number PA16-0719. Patients aged ≥18 years with undiagnosed pleural effusion who underwent pleuroscopy were included. Factors including medical history and laboratory and radiology results were abstracted from patients' medical records. To identify our cases, we reviewed pleuroscopy procedure codes using MD Anderson's clinical database search.
Definitions and diagnostic outcomes
Pleuroscopy results were classified as follows according to final histopathological diagnosis: 1. Malignant: pathology report with malignancy. 2. Non-specific pleuritis: pathology report with any of the following: reactive fibrous pleural thickening, fibrinous pleurisy, fibrosis, florid-reactive change, florid inflammation, fibrous connective tissue, chronic inflammation, benign change or dense fibrous tissue, in the absence of malignant pleural infiltration, granulomata, pleural vasculitis or evidence of bacterial infection. The final diagnosis was determined by the treating team and was based on pathology reports and clinical, microbiology and radiological data. The following terminology was used to describe the final diagnosis: 1. Malignancy: malignant cells on histopathology or any follow-up testing. Malignancy was then classified as:
• Primary malignant: consistent with the patient's underlying active malignancy.
• Other malignant: different from the patient's underlying active malignancy. 2. Specific benign: benign pleural inflammation with histopathological and/or clinical characteristics consistent with chemotherapy-induced pleuritis (CIP), possible radiation-induced pleuritis (RIP), other paramalignant pleuritis, other benign pleuritis or infectious pleuritis. Patients had to show no evidence of malignancy for a minimum of 6 months follow-up.
• CIP: pleural effusion in a patient receiving chemotherapy known to cause pleural effusions and who had no other cause for pleural effusion. Chemotherapy associated with pleural effusions was identified using published tables. 10, 11 Agents not appearing in these tables were cross-checked using an online database. 12 • Possible RIP: effusion that develops in a patient who received radiation in the previous 18 months, whose effusion exclusively involved the lung and pleura that were irradiated, did not also receive chemotherapy known to cause pleural effusion and had no other cause for pleural effusion. This definition was adapted from criteria offered by Bachman and Macken. 13 The phenomenon of RIP is poorly supported in the literature and the exact nature and definition of this clinical entity remains controversial. We propose our definition based on our clinical observations and the limited evidence available.
• Other paramalignant pleuritis: pleural effusion that develops in a patient who received prior therapy for their malignancy but did not meet criteria for CIP or RIP (e.g. patients who received both chemotherapy and radiation and could not be placed in one category only, patient with endorgan damage due to treatment effects or any other complication related to the treatment for malignancy).
• Other benign pleuritis: pleural effusion secondary to another specific diagnosis not related to therapy for malignancy (e.g. benign asbestos pleural effusion (BAPE)).
• Infectious pleuritis: pleural effusion secondary to an infectious cause determined by histopathology or tissue culture. 3. Idiopathic pleuritis: pathology report with any of the following: reactive fibrous pleural thickening, fibrinous pleurisy, fibrosis, florid-reactive changes, fibrous connective tissue, chronic inflammation, benign change or dense fibrous tissue in the absence of malignant pleural infiltration, granulomata, pleural vasculitis or evidence of infection. Patients had to show no evidence of malignancy or other specific benign diagnoses for a minimum of 6 months follow-up. The performance of pleuroscopy to diagnose malignancy was evaluated using sensitivity and specificity methods, and likelihood ratios (LR). We considered all patients with a final diagnosis of malignancy on final pathology result to have malignancy; this served as the reference standard of truth. Patients with no malignancy on final diagnosis were considered to have no malignancy after minimum 6 months of follow-up.
Statistical analysis
We used descriptive statistics to summarize the demographic and clinical characteristics of all patients studied. Categorical data were compared with the Fisher exact test and chi-square test. Nonparametrically distributed data were compared with the Kruskal-Wallis test. The sensitivity, specificity, positive predictive value and negative predictive value were estimated for all patients and for patients in prespecified subgroups of interest: malignancy or no malignancy.
P-values of < 0.05 were considered statistically significant. All tests were two-sided. All statistical analyses were performed with use of STATA software, version 13 (StataCorp LP, College Station, TX, USA).
RESULTS
All patients in this study had suspected malignancy and an undiagnosed exudative pleural effusion. None had a diagnosis of pleural infection before pleuroscopy. Of the 199 patients reviewed, 172 (86%) had a history of active malignancy. These patients were included in our main analysis. A median of 10 biopsies were performed per patient (Table 1) . Of the 172 patients with active malignancy, 73 (42%) had a malignant effusion by histopathology, 9 (5%) had eosinophilic pleuritis and 90 (52%) had non-specific pleuritis. Three patients (3%) with non-specific pleuritis were diagnosed with malignancy at follow-up. Specific benign effusions were diagnosed in 65 of 172 patients; 24 with CIP, 27 with RIP, 11 with other paramalignant pleuritis and 3 with other benign pleuritis. Idiopathic pleuritis was diagnosed in 31 of 172 patients.
CIP was diagnosed in 24 patients (see Table 2 for causative agents). The mean time from last chemotherapy to the development of effusion was 38 AE 10 days. All but one patients were monitored for at least 6 months with a mean follow-up of 24.2 AE 10.0 months. Most patients (22/24) had minimal residual effusion on follow-up imaging. Two patients had recurrence of effusion with a chemotherapy rechallenge, and cytology was negative for malignancy on a second thoracentesis. Both patients were rechallenged with docetaxel. One patient with myelodysplastic syndrome died of complications resulting from infection, hence no imaging follow-up was done at 6 months. The second patient had resolution of their pleural effusion at 3 months. Pathology findings showed chronic pleuritis with mesothelial hyperplasia in 22 patients (92%) and fibrinous pleuritis in 2 (8%). In addition to chronic pleuritis with mesothelial hyperplasia, one patient had a multinucleated giant cell reaction, six had eosinophilic infiltration as noted prior and one had granulomatous changes. Possible RIP was diagnosed in 27 patients: 21 patients received radiation therapy for lung cancer, 3 for lymphoma and 3 for other non-lung malignancy. All patients had an exudative pleural effusion with lymphocyte predominance. The mean time from last radiation treatment to the development of pleural effusion was 11.4 AE 8.9 months. The total radiation per patient was in accordance with accepted practice standards (see Table S1 (Supplementary Information) for radiation doses). All patients were monitored for at least 6 months with a mean follow-up of 24.9 AE 17.7 months. All patients had minimal residual effusion or resolution on follow-up imaging. The parietal pleura of these patients were described intraoperatively as whitish discolouration, frequently thickened and occasionally with clear delineation between normal pleura and discoloured pleura coinciding with the radiation field (Fig. 1) . Pathology findings showed fibrinous pleuritis in 11 patients (41%) and chronic pleuritis AE mesothelial hyperplasia in 16 patients (59%).
Other paramalignant pleuritis occurred as an adverse effect of cancer therapy in 11 patients (see Table S2 (Supplementary Information) for aetiologies).
Other benign pleuritis was diagnosed in three patients, all of whom had BAPE. No underlying pleural malignancy was evident after a mean follow-up period of 9.9 AE 1.9 months. All patients had an eosinophilic exudative pleural effusion.
Idiopathic pleuritis was diagnosed in 31 patients. These patients were monitored for a mean of 23.0 AE 11.0 months and none were diagnosed with malignant pleural disease.
Performance of pleuroscopy in patients with active malignancy
Of the 76 patients eventually diagnosed with malignancy, pleuroscopy was diagnostic in 73. The sensitivity of pleuroscopy was 96% (95% CI: 89-99%) ( Table 3) . Fluorodeoxyglucose-avid pleural-based nodules on combined positron emission tomography-computed tomography scan were seen more often in patients with a final diagnosis of malignancy (P < 0.001).
A new malignancy, other than the primary malignancy already diagnosed, was found in 7 of 76 patients (9%). Non-small cell lung cancer was diagnosed in four, whereas angiosarcoma and thymic carcinoma were diagnosed in the other three patients. Pleuroscopy was diagnostic in six of the seven patients. Video-assisted thoracoscopic surgery (VATS) established the diagnosis of thymic carcinoma. Pleuroscopy results compared with the final diagnoses are shown in Table 4 . There were no patients of infectious pleural effusion.
The LR of each finding is shown in Table S3 (Supplementary Information) with additional details provided in Appendix S1 (Supplementary Information).
DISCUSSION
Our study showed a large number of patients, with active malignancy who were diagnosed with nonmalignant pleural effusions by pleuroscopy (58%). Surprisingly, this is comparable to the prevalence of malignancy in other studies of pleuroscopy where the patient population was more general. 6, 7, [14] [15] [16] [17] [18] [19] Review of clinical and radiographical data was sufficient to reach a diagnosis in 70% of patients, the majority of which were related to cancer therapy. Our study also showed that initial pleuroscopy established the diagnosis of malignancy in 73 of 76 patients who had a final diagnosis of malignancy after at least 6 months follow-up. Therefore, pleuroscopy had an overall sensitivity of 96% for the diagnosis of malignancy. The sensitivity of pleuroscopy in this study is similar to previous studies. [20] [21] [22] We also found that 6 out of 24 patients with CIP had eosinophilic pleuritis on histopathology. Eosinophilic pleuritis or pleural fluid eosinophilia (≥ 10% eosinophils) is reported in many conditions [23] [24] [25] but appears less common in patients with tuberculosis and malignancy. 26 Our study corroborates these findings and suggest that eosinophilic pleuritis in patients with active malignancy is more likely secondary to chemotherapy or BAPE, rather than malignancy in the correct clinical context.
In patients where histopathology is negative for malignancy and does not show eosinophilic pleuritis, findings are usually non-specific. In the absence of additional clinical information, these patients are diagnosed with non-specific pleuritis. In patients with a known history of malignancy, interpreting a histopathological diagnosis of non-specific pleuritis is challenging as the risk associated with a false-negative result is high.
The optimum follow-up for patients with nonspecific pleuritis by histopathology is unclear and may depend on the patient population. In a retrospective study of patients who underwent pleuroscopy, 11% diagnosed with non-specific pleuritis developed malignancy over a mean follow-up period of 9.8 AE 4.6 months. 5 Mesothelioma was diagnosed in all cases and all patients had known asbestos exposure. In another study, 7% of patients developed malignancy over a mean follow-up of 32.9 AE 27.4 months. 8 Three patients developed mesothelioma and two developed lung carcinoma. In a recent study designed to evaluate optimum duration of follow-up for non-specific pleuritis, 3.5% of patients developed malignancy with a mean time to diagnosis of 6.8 AE 4.2 months. 27 Again, all patients developed mesothelioma.
In a cohort with active malignancy, the indication for pleuroscopy is commonly to diagnose recurrence or metastasis. In such patients, the de novo diagnosis of mesothelioma is less likely than those with a history of asbestos exposure referred for pleuroscopy. We speculate that 6 months is sufficient follow-up for nonspecific pleuritis in patients with active malignancy, as those with false-negative results would likely have advanced disease and clinically develop obvious deterioration in that time. If a diagnosis of malignant effusion was made after 6 months, it would likely represent a new process.
Although not directly diagnostic, non-specific pleuritis on histopathology in our patient population is informative as the primary indication for pleuroscopy is to rule out malignancy. That said, patients with cancer frequently develop distressing pulmonary symptoms during the course of treatment and follow-up. Establishing the aetiology of a benign effusion may also be important. In our cohort, many patients with nonspecific pleuritis had effusions related to cancer therapy, which we term paramalignant. Those with eosinophilic pleuritis had chemotherapy-associated pleuritis or BAPE, which suggests that eosinophilia by histopathology may favour a non-malignant diagnosis.
RIP has been described in case reports and case series. 13, 28 The largest series reported that 5% of patients receiving radiation for breast cancer developed RIP. In all patients, pleural effusion appeared within 18 months after radiation and was accompanied by radiation pneumonitis. 13 Similarly, all patients in our study diagnosed with RIP had parenchymal radiation changes. On direct visualization of the pleura during pleuroscopy, a sharp border frequently demarcated pleura contained within the radiation port from pleura outside the field. This mirrors demarcation of lung parenchyma seen intraoperatively and radiographically in patients who received chest or lung irradiation. 29, 30 CIP may occur as an isolated disorder or accompanied by parenchymal disease. The underlying pathogenic mechanisms are uncertain and may include hypersensitivity reactions, oxidative stress of mesothelial cells, dose-dependent toxic effects, fluid retention and induction of chemical inflammation. 31 As more chemotherapeutic drugs are developed, it is expected that an increasing number of pathogenic mechanisms will be implicated in pleural disease. In all patients with CIP, a temporal relationship was found between the period of chemotherapy use and the development of effusion. Cessation of chemotherapy led to resolution of pleural effusion in all except two patients, who were rechallenged with the same drug.
In addition to direct toxic effects of radiation and chemotherapy on the pleura, these treatment modalities are frequently associated with systemic toxicities that lead to pleural effusion. For example, pulmonary oedema is common in patients receiving chemotherapy as aggressive hydration is usually part of administration protocols to reduced toxicity. Patients who develop end-organ injury such as renal, liver or cardiac insufficiency may also develop pleural effusions from systemic volume overload and low albumin states.
Finally, 31 patients with non-specific pleuritis were unable to be classified and designated as idiopathic pleuritis. Of course, a cause for their exudative effusion must be present, it simply could not be determined by histopathology and review of clinical details.
Our study has several limitations. This is a retrospective cohort analysis and is inclined to selection bias, as only referred patients suitable for pleuroscopy were included in this study. The definition of RIP is also controversial as this disease is poorly described. An accepted timeframe from exposure and other diagnostic criteria are not established; therefore, the diagnosis of RIP in our cohort may not be comparable to other studies where different criteria were used. It is also possible that patients were either under-or overdiagnosed with RIP based on the criteria we selected.
In conclusion, the sensitivity of pleuroscopy to detect malignancy in patients with active malignancy is high. The prevalence of malignant pleural disease was lower than expected for this patient population. Patients without malignancy on histopathology were most likely to have non-specific pleuritis, a cause for which was identified in a majority of cases after clinical review. In the few patients with eosinophilic pleuritis, none developed malignancy.
